Evidence map›Paper›PMID 35222383›Full record

ArticleFrontiers in immunology2022

A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer.

Mingjia Xiao, Xiangjing Liang, Zhengming Yan, Jingyang Chen, Yaru Zhu, Yuan Xie, Yang Li, Xinming Li, Qingxiang Gao, Feiling Feng and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mingjia XiaoDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xiangjing LiangUltrasound Medical Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhengming YanDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Jingyang ChenFirst College of Clinical Medicine, Southern Medical University, Guangzhou, China.
Yaru ZhuDepartment of Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yuan XieDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Yang LiDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Xinming LiDepartment of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Qingxiang GaoDepartment of Biliary Surgery I, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Feiling FengDepartment of Biliary Surgery I, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Gongbo FuDepartment of Medical Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Yi GaoDepartment of Hepatobiliary Surgery II, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PACA), which is characterized by an immunosuppressive nature, remains one of the deadliest malignancies worldwide. Aberrant DNA methylation (DNAm) reportedly influences tumor immune microenvironment. Here, we evaluated the role of DNA methylation driven genes (MDGs) in PACA through integrative analyses of epigenomic, transcriptomic, genomic and clinicopathological data obtained from TCGA, ICGC, ArrayExpress and GEO databases. Thereafter, we established a four-MDG signature, comprising GPRC5A, SOWAHC, S100A14, and ARNTL2. High signature risk-scores were associated with poor histologic grades and late TNM stages. Survival analyses showed the signature had a significant predictive effect on OS. WGCNA revealed that the signature may be associated with immune system, while high risk-scores might reflect immune dysregulation. Furthermore, GSEA and GSVA revealed significant enrichment of p53 pathway and mismatch repair pathways in high risk-score subgroups. Immune infiltration analysis showed that CD8+ T cells were more abundant in low score subgroups, while M0 macrophages exhibited an opposite trend. Moreover, negative regulatory genes of cancer-immunity cycle (CIC) illustrated that immunosuppressors TGFB1, VEGFA, and CD274 (PDL1) were all positively correlated with risk-scores. Furthermore, the four signature genes were negatively correlated with CD8+ lymphocytes, but positively associated with myeloid derived suppressor cells (MDSC). Conversely, specimens with high risk-scores exhibited heavier tumor mutation burdens (TMB) and might show better responses to some chemotherapy and targeted drugs, which would benefit stratification of PACA patients. On the other hand, we investigated the corresponding proteins of the four MDGs using paraffin-embedded PACA samples collected from patients who underwent radical surgery in our center and found that all these four proteins were elevated in cancerous tissues and might serve as prognostic markers for PACA patients, high expression levels indicated poor prognosis. In conclusion, we successfully established a four-MDG-based prognostic signature for PACA patients. We envisage that this signature will help in evaluation of intratumoral immune texture and enable identification of novel stratification biomarkers for precision therapies.

Indexed as

DNA MethylationPancreatic NeoplasmsDNAHumansPrognosisReceptors, G-Protein-CoupledTumor MicroenvironmentDNAGPRC5A protein, humanReceptors, G-Protein-CoupledDNA methylation driven genepancreatic cancerprecision medicineprognostic signaturetumor immune

Identifiers

PMID35222383
PMCPMC8866195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.